ONC 001 - OncoPrecision
Alternative Names: ONC-001-OncoPrecisionLatest Information Update: 22 Jan 2026
At a glance
- Originator OncoPrecision
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action IgG receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Chronic myelomonocytic leukaemia
Most Recent Events
- 15 Dec 2025 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route)
- 15 Dec 2025 Preclinical trials in Chronic myelomonocytic leukaemia in USA (unspecified route)
- 01 Dec 2025 OncoPrecision is actively exploring strategic collaborations and partnerships to accelerate the development and commercialization of its programs